Left Ventricular Cardiomyopathy in Mitral Valve Prolapse: Fact or Fiction? - European Medical Journal
×

Browse

Left Ventricular Cardiomyopathy in Mitral Valve Prolapse: Fact or Fiction?

| Cardiology Download as | PDF
Authors:
*Christina Attenhofer Jost,1 Matthias Greutmann,2 Heidi M. Connolly,3 Barbara Naegeli,1 Anja Faeh-Gunz,1 Christoph Scharf,1 Reto Candinas,1 Emanuela Valsangiacomo Buechel,4 Roland Weber,4 Christian Binggeli,1 Olaf Franzen,1 Argelia Medeiros-Domingo5
Disclosure:

No potential conflict of interest.

Received:
18.11.14
Accepted:
06.01.15
Citation
EMJ Cardiol. ;3[1]:30-37.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

In most patients with mitral valve prolapse (MVP) without severe mitral regurgitation (MR), left ventricular (LV) function is preserved. There are, however, patients with MVP who have unexplained LV dilatation  and/or decreased LV function. An association between MVP and sudden cardiac death has also been reported. LV size and function may be affected by the type of MVP, severity of regurgitation, and cause of MVP (myxomatous degeneration versus fibroelastic deficiency). There is increasing evidence suggesting an intrinsic cardiomyopathy associated with MVP. The cardiomyopathy associated with MVP can also affect  the right ventricle (RV). Although the impact on ventricular dimensions and function are usually subtle, these abnormalities can affect clinical and echocardiographic estimation of the severity of MR and may thus have an impact on therapeutic decisions. Particularly in patients with the most extreme forms of MVP (Barlow disease), and in patients with Marfan syndrome or other connective tissue disorders, a cardiomyopathy affecting the LV and RV may thus occur occasionally. A better understanding of LV impairment associated with MVP is important for risk assessment and clinical decision-making.

Please view the full content in the PDF above.